REIMAGINE WHAT'S POSSIBLE FOR
ITCH RELIEF & SKIN CLEARANCE

Helen, real RINVOQ patient

INDICATION

RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.

Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

Rapid & Durable Response1-3

Itch reduction* observed 2 days after first dose and measured at Week 16

75% skin improvement† observed 2 weeks after first dose and measured at Week 16

Clear or almost clear skin‡ measured at Week 16

Itch and skin improvement rates observed at ~4 years§

*Improvement in WP-NRS ≥4.

†EASI 75.

‡vIGA 0/1.

§Based on non-ranked, not statistically significant data. No conclusions can be made.

See Itch Relief & Skin Clearance Data

Higher-Level Disease Control in Both Itch & Skin4,5

Defined by simultaneous achievement of WP-NRS 0/1 & EASI 90; higher than WP-NRS ≥4 improvement and EASI 75. Itch and skin are clinical features of AD; other outcome measures may exist.

Explore the LEVEL UP open-label study results:

  • Head-to-head data for RINVOQ vs DUPIXENT®# (dupilumab)
  • Switch data for RINVOQ among DUPIXENT inadequate responders (<EASI 75)

#DUPIXENT is a registered trademark of Sanofi Biotechnology. See US Prescribing Information for further information.

See LEVEL UP results
See Footnotes & Definitions

Please see Important Safety Information, including BOXED WARNING on Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis, below.

Learn more about these and the full Important Safety Information below 
Number 1 prescribed oral JAK inhibitor for AD.

#As of 7/2024. Source: Integrated Symphony Health (PatientSource) and IQVIA (NSIP).

 

Greater than 10k RINVOQ AD prescribers.

**As of 02/2025. Source: IQVIA+SPP Xponent TRx data.

††Across all specialties.

 

Strongest level of recommendation in AAD AD guidelines.

‡‡Strong recommendation for the use of an intervention: benefits clearly outweigh risks and burdens.

The certainty of the evidence was assessed as Moderate, which indicates moderate confidence in the effect estimate.

No therapy received a High Certainty of Evidence.

§§Inclusion in phototherapy and systemic AAD adult AD Guidelines does not denote endorsement or recommendation of product used by AAD.

~1 in 4 AD patients prescribed RINVOQ were bio-naïve. All patients were post-systemic therapy.

¶¶As of 06/2024. Source: SHA + IQVIA.

|| ||All patients were post-systemic therapy.

~6 Years of Safety Data in AD10

Explore Long-Term Data
RINVOQ® (upadacitinib) packaging.

One Pill, Once Daily1

RINVOQ is an oral, once-daily therapy.1

For adults <65 years and pediatric patients 12+ years weighing at least 40 kg (88 lb), initiate treatment with RINVOQ 15 mg once daily in pediatric patients (≥12 years, ≥40 kg) and adults <65 years of age. If an adequate response is not achieved, consider increasing the dosage to 30 mg once daily. Discontinue RINVOQ if an adequate response is not achieved with the 30 mg dose. Use the lowest effective dose needed to maintain response. For patients ≥65 years, patients receiving strong CYP3A4 inhibitors, and patients with severe renal impairment, the recommended dose of RINVOQ is 15 mg once daily. Coadministration of RINVOQ with strong CYP3A4 inducers is not recommended.1

See Dosing & Monitoring Information
Request Samples

Patient Support Services

RINVOQ Complete
to help patients start and stay
on track with their prescribed
treatment plan

Learn About RINVOQ Complete

Resources & Forms
to support your patients

Download Resources & Forms